Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR)
Cedarbaum JM, Silvestri M, Clark M, Toy L, Harts A, Green-Parsons A, McDowell FH. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR). Journal Of Neural Transmission: Parkinson's Disease A And Dementia Section 1990, 2: 205-213. PMID: 2257060, DOI: 10.1007/bf02257651.Peer-Reviewed Original ResearchConceptsStandard SinemetMotor response fluctuationsResponse fluctuationsSinemet CRDisease patientsControlled-release levodopa/carbidopaLevodopa/carbidopaLong-term treatmentParkinson's disease patientsLong-term managementAntiparkinson effectEligible patientsMost patientsMedication dosesInterdose intervalClinical trialsParkinson's diseaseUseful adjunctPatientsSinemetDiseaseYearsCarbidopaAdjunctDoseL-Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinson's Disease.
Cedarbaum JM, Silvestri M, Clark M, Harts A, Kutt H. L-Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinson's Disease. Clinical Neuropharmacology 1990, 13: 29. PMID: 2106391, DOI: 10.1097/00002826-199002000-00003.Peer-Reviewed Original ResearchConceptsParkinson's diseaseResponse fluctuationsL-deprenylTherapeutic response fluctuationsTotal levodopa doseOpen-label trialPlasma levodopa concentrationsPlasma levodopa levelsEffect of deprenylWeeks of treatmentDaily levodopaLevodopa doseLevodopa pharmacokineticsPeripheral pharmacokineticsAction of MAOLevodopa treatmentMost patientsDOPAC levelsLevodopa levelsDopaminergic activityLevodopa concentrationsMild endDose failureTherapeutic actionPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply